Evidence map›Paper›PMID 32872139›Full record

ArticleVaccines2020

Characterization of the Maternally Derived Antibody Immunity against Rhdv-2 after Administration in Breeding Does of an Inactivated Vaccine.

Massimiliano Baratelli, Joan Molist-Badiola, Alba Puigredon-Fontanet, Mariam Pascual, Oriol Boix, Francesc Xavier Mora-Igual, Michelle Woodward, Antonio Lavazza, Lorenzo Capucci

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Characterisation ofInternational journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Immunity againstVaccines · 2021
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Massimiliano BaratelliHIPRA, 17170 Amer, Spain.ORCID 0000-0001-5990-4045
Joan Molist-BadiolaHIPRA, 17170 Amer, Spain.
Alba Puigredon-FontanetHIPRA, 17170 Amer, Spain.
Mariam PascualInstitute of Agrifood Research and Technology (IRTA), 08140 Barcelona, Spain.
Oriol BoixHIPRA, 17170 Amer, Spain.
Francesc Xavier Mora-IgualAsvet Veterinaris, 08410 Barcelona, Spain.
Michelle WoodwardHIPRA, 17170 Amer, Spain.ORCID 0000-0002-1845-9165
Antonio LavazzaIstituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), 25124 Brescia, Italy.ORCID 0000-0002-7646-3592
Lorenzo CapucciIstituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna (IZSLER), 25124 Brescia, Italy.ORCID 0000-0002-1830-3929
Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini" · ITInstitute of Agrifood Research and Technology · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inactivated strain-specific vaccines have been successfully used to control rabbit haemorrhagic disease (RHD) caused by RHDV-2 in the rabbit industry. It is unknown whether and how vaccination of breeding does contributed to protect the population of young susceptible rabbit kits. The present study investigates whether the immunity against RHDV-2 produced by vaccination of breeding does is transmitted to their progeny and its dynamic once inherited by kits. For this purpose, New Zealand female rabbits of 8-9 weeks of age were allocated into 2 groups of 40 subjects each and bred during 6 reproductive cycles. The first experimental group was vaccinated with a commercially available inactivated vaccine against RHDV-2 whereas the second group was inoculated with PBS. Moreover, the present study was also meant to identify the mechanisms of transmission of that maternal immunity. For this reason, rabbit kits of vaccinated and non-vaccinated breeding does were cross-fostered before milk uptake. The RHDV-2 antibody response was monitored in the blood serum of breeding does and of their kits by competition ELISA (cELISA) and solid-phase ELISA (spELISA). Since it has been clearly demonstrated that cELISA positive rabbits are protected from RHD, we avoided the resorting of the challenge of the kits with RHDV-2. Results showed that RHDV-2 antibodies were inherited by kits up to one year from vaccination of breeding does. Once inherited, the maternally derived antibody response against RHDV-2 lasted at least until 28 days of life. Finally, the study also elucidated that the major contribution to the maternal derived immunity against RHDV-2 in kits was provided during gestation and probably transmitted through transplacental mechanisms although lactation provided a little contribution to it. The present study contributed to elucidate the characteristics of the maternal antibody immunity produced by vaccination and its mechanisms of transmission.

Indexed as

inactivated vaccinesmaternal derived immunityrabbitsRHDV-2

Identifiers

PMID32872139
PMCPMC7564433
OpenAlexW3082383651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.